Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Sarah Larson, Umar Farooq, Tahir Latif, Felix Mensah, Bradley Hunter, Stefan Ciurea, Nebu Koshy, Locke Bryan, Boyu Hu, William Clark, Hassaan Yasin, Yeonhee Kim, Greg Kaufman, Akil Merchant

Blood (2025) 146 (Supplement 1): 668.

https://doi.org/10.1182/blood-2025-668

Published: 2025

Journal Articles

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 402.

https://doi.org/10.1182/blood-2025-402

Published: 2025

Journal Articles

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Blood (2025) 146 (Supplement 1): 401.

https://doi.org/10.1182/blood-2025-401

Published: 2025

Journal Articles

Age-related differences in presentation among pediatric, adolescent, and young adults with mixed cellularity vs. nodular sclerosis histology Hodgkin lymphoma on Children's oncology group treatment and registry trials

Mallorie Heneghan, Lindsay Renfro, Yue Wu, Angela Feraco, Jamie Flerlage, Boyu Hu, Erin Marcotte, Cindy Schwartz, Kara Kelly, Sharon Castellino, Justine Kahn

Blood (2025) 146 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2025-1849

Published: 2025

Journal Articles

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Hannah Willis, Joshua Horns, Kelsey Baron, Allison Bock, Lindsey Fitzgerald, Narendranath Epperla, Harsh Shah, Boyu Hu, Deborah Stephens, Adam Kittai, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6316.

https://doi.org/10.1182/blood-2025-6316

Published: 2025

Journal Articles

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2025-4499

Published: 2025

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Jennifer Woyach, Danielle Brander, Boyu Hu, Kerry Rogers, Zulfa Omer, Emily Curran, Deborah Stephens, Andrea Sitlinger, Yi Chen, Stephen Anthony, Yu Chen, Kewei Shang, John Byrd

Blood (2025) 146 (Supplement 1): 87.

https://doi.org/10.1182/blood-2025-87

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Sandeep Raj, Allison Bock, Sharmila Giri, Dilan Patel, Madiha Iqbal, Natalie Grover, Lori Leslie, Marcus Geer, Olalekan Oluwole, Boyu Hu, Grzegorz Nowakowski, Miguel-Angel Perales

Blood (2025) 146 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2025-3748

Published: 2025

Journal Articles

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Narendranath Epperla, Allison Bock, Yizhe Xu, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Kelsey Baron, Daniel Ermann, Joe Mendez, Lindsay Burt, Donald Cannon, Amit Maity, Joshua Palmer, Iyad Alnahhas, Thomas Ollila

Blood (2025) 146 (Supplement 1): 8241.

https://doi.org/10.1182/blood-2025-8241

Published: 2025

Journal Articles

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

Narendranath Epperla, Yizhe Xu, Allison Bock, Kelsey Baron, Lindsey Fitzgerald, Harsh Shah, Daniel Ermann, Lalit Sehgal, Lapo Alinari, Boyu Hu

Blood (2025) 146 (Supplement 1): 8235.

https://doi.org/10.1182/blood-2025-8235

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Blood (2025) 146 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2025-3617

Published: 2025

Journal Articles

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

Narendranath Epperla, Allison Bock, Boyu Hu, Yizhe Xu, Lindsey Fitzgerald, Daniel Ermann, Harsh Shah, Kelsey Baron, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 3616.

https://doi.org/10.1182/blood-2025-3616

Published: 2025

Journal Articles

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Kelsey Baron, Charlotte Wagner, Lindsey Fitzgerald, Amber Jacoway, Ausha Marden, Daniel Ermann, Boyu Hu, Harsh Shah, Narendranath Epperla, Allison Bock

Blood (2025) 146 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2025-4485

Published: 2025

Journal Articles

Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)

Narendranath Epperla, Allison Bock, Boyu Hu, Joe Mendez, Lauren Schaff, Thomas Kaley, Ingo Mellinghoff, Christian Grommes

Blood (2025) 146 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2025-1972

Published: 2025

Journal Articles

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Blood (2025) 146 (18): 2177–2188.

https://doi.org/10.1182/blood.2025029117

Published: 2025

Includes: Supplemental data

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Age-related differences in presentation among pediatric, adolescent, and young adults with mixed cellularity vs. nodular sclerosis histology Hodgkin lymphoma on Children's oncology group treatment and registry trials

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only